Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
05
2020
revised:
18
09
2020
accepted:
25
09
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
We aimed to retrospectively investigate the prognostic worth of pretreatment advanced lung cancer inflammation index (ALI) in locally advanced nasopharyngeal carcinoma (LA-NPC) patients treated with concurrent chemoradiotherapy (C-CRT). The ROC curve analyses distinguished a rounded ALI cut-off score of 24.2 that arranged the patients into two cohorts [ALI ≥ 24.2 ( As a novel prognostic index, the pretreatment ALI < 24.2 appeared to be strongly associated with significantly diminished survival outcomes in LA-NPC patients treated with C-CRT independent of the universally recognized T- and N-stages.
Identifiants
pubmed: 33082783
doi: 10.1155/2020/3127275
pmc: PMC7563083
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3127275Informations de copyright
Copyright © 2020 Erkan Topkan et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest regarding the publication of this paper.
Références
J Hepatol. 2014 Aug;61(2):396-407
pubmed: 24751830
Cancer Med. 2017 Jan;6(1):310-319
pubmed: 27860387
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Medicine (Baltimore). 2017 Jul;96(29):e7577
pubmed: 28723793
J Support Oncol. 2007 Apr;5(4):157-62; discussion 164-6, 183
pubmed: 17500503
Cancer Med. 2018 Dec;7(12):6010-6019
pubmed: 30406969
Crit Rev Oncol Hematol. 2018 Jul;127:91-104
pubmed: 29891116
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Acta Haematol. 2017;137(2):76-85
pubmed: 28076862
Jpn J Clin Oncol. 2018 Mar 1;48(3):265-271
pubmed: 29294009
Eur Arch Otorhinolaryngol. 2019 May;276(5):1487-1492
pubmed: 30877423
Asia Pac J Clin Nutr. 2003;12(3):257-60
pubmed: 14505986
J Am Diet Assoc. 2004 Aug;104(8):1258-64
pubmed: 15281044
Clin Otolaryngol. 2020 Mar;45(2):167-176
pubmed: 31573757
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Clin Nutr. 2008 Dec;27(6):793-9
pubmed: 18718696
Onco Targets Ther. 2014 Sep 30;7:1811-5
pubmed: 25336972
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
BMC Cancer. 2019 Mar 18;19(1):241
pubmed: 30885163
Proc Nutr Soc. 1999 Aug;58(3):681-3
pubmed: 10604203
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
Acta Otolaryngol. 2017 Jul;137(7):778-785
pubmed: 28125312
Cancer Manag Res. 2019 Oct 07;11:8807-8815
pubmed: 31632140
Ear Nose Throat J. 2019 Jun 10;:145561319856327
pubmed: 31184210
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Medicine (Baltimore). 2016 Jan;95(2):e2380
pubmed: 26765414
Clin Lung Cancer. 2015 Nov;16(6):e165-71
pubmed: 25922292
Eur J Cancer. 2013 May;49(8):1923-31
pubmed: 23434149
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Clin Cancer Res. 2010 Jul 15;16(14):3754-9
pubmed: 20628028
Nat Rev Cancer. 2013 Nov;13(11):759-71
pubmed: 24154716
Future Oncol. 2020 Feb;16(5):117-127
pubmed: 31789058
BMC Cancer. 2013 Mar 27;13:158
pubmed: 23530866
Crit Rev Oncol Hematol. 2018 Dec;132:130-137
pubmed: 30447918
Tumour Biol. 2011 Apr;32(2):317-24
pubmed: 21052888
Onkologie. 2012;35(9):494-8
pubmed: 23007146
Int J Biol Markers. 2019 Jun;34(2):139-147
pubmed: 30864463
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468